Skip to main content
. 2022 Jul 7;15:244. doi: 10.1186/s13104-022-06107-y

Table 2.

Primary, maternal, and perinatal outcomes (number (percent); median [interquartile range])

Outcome Placebo (n = 9) Sildenafil (n = 11) P-value*
Primary outcome
 Gestational age at delivery (weeks + days) 29+2 [28+1, 34+1] 26+4 [25+6, 31+0] 0.200
Maternal
 Symptomatic hypotension 0 (0%) 0 (0%) NA
 Pre-eclampsia 3 (33.3%) 0 (0%) 0.211
 Mode of delivery 0.348
 Termination of pregnancy 1 4
 Vaginal birth 0 1
 Classical Caesarean section 4 4
 Lower segment Caesarean section 4 2
 Haemorrhage requiring transfusion 1 (11.1%) 0 (0%) 0.918
Perinatal
 Fetal growth velocity
 Biparietal diameter (mm/days) 0.36 [0.32, 0.49] 0.37 [0.26, 0.39] 0.508
 Head circumference (mm/days) 1.28 [1.03, 2.07] 1.21 [1.04, 1.52] 0.605
 Abdominal circumference (mm/days) 1.05 [0.97, 1.21] 1.37 [1.10, 1.38] 0.310
 Femur length (mm/days) 0.28 [0.20, 0.31] 0.24 [0.16, 0.30] 0.627
 Estimated fetal weight (g/days) 10.80 [6.07, 11.82] 7.19 [5.62, 9.40] 0.667
 Deepest vertical amniotic fluid pocket (mm/days) 0.007 [0.000, 0.009] 0.013 [0.007, 0.070] 0.181
 Stillbirth 1 (11.1%) 4 (36%) 0.436
 Neonatal death 1 (11.1%) 1 (9%) 1
 Intact survival 7 (77.8%) 6 (55%) 0.528
 Persistent pulmonary hypertension of the newborn 0 (0%) 2 (18%) 0.164

* Fisher’s exact (dichotomous) or Mann Whitney U (continuous) test

Defined as survival to estimated due date without evidence of severe central nervous system injury (by ultrasound and/or magnetic resonance imaging)